Prasinezumab

Prasinezumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting SNCA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Prasinezumab (PRX002/RG7935) is an investigational monoclonal antibody that targets α-synuclein, a protein that is believed to misfold and aggregate to form the protein structures that are highly implicated in Parkinson’s disease pathology. Prasinezumab targets α-synuclein and is being developed through a worldwide collaboration with Roche as a potentially disease modifying therapy that is designed to slow or reduce the neurodegeneration associated with α-synuclein misfolding and/or its transmission.

Target	SNCA
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	1960462-19-4
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on SNCA

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue